Thermo Fisher Scientific CEA Monoclonal Antibody (3C5C10)

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.05-0.2 µg/mL

-

Product Specifications

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

3C5C10

Immunogen

native CEA protein (Swiss-Prot: P06731) if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CD66e (CEACAM5),uniProtId:P06731-1,ncbiNodeId:9606,antigenRange:1-702,antigenLength:702,antigenImageFileName:A01787-5_CD66e_CEACAM5_P06731-1_House_mouse.svg,antigenImageFileNamePDP:A01787-5_CD66e_CEACAM5_P06731-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Wet ice

Product Specific Information

Carcinoembryonic antigen (CEA) is a complex glycoprotein of molecular weight 200 kDa. In healthy adults, less than 5 ng/ml of CEA is found in the serum. Elevation of CEA antigen is found in the blood of patients with cancer of the lung, liver, pancreas, breast, cervix, prostate and so on. CEA measurement is mainly used as a tumor marker to identify recurrences after surgical resection, or localize cancer spread though dosage of biological fluids. The CEA blood test is not reliable for diagnosing cancer. CEA levels may also be raised in some conditions like ulcerative colitis, pancreatitis and cirrhosis.GenScript Human CEA Antibody, mAb, Mouse is produced from the hybridoma resulting from fusion of SP2/0-Ag14 myeloma and B-lymphocytes obtained from mouse immunized with native human CEA protein (Swiss-Prot: P06731).

Target Information

CEA (Carcino Embryonic Antigen, CD66e) is synthesized during development in the fetal gut, and re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is a member of carcinoembryonic antigens, immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable) and six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3). Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60 to 70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA is a member of a large family of glycoproteins, a useful tumor marker for adenocarcinoma, and found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. CEA was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, CEA was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.